Yes. Stella+ GHK is a compounded prescription topical medication containing tretinoin (teratogenic retinoid), estriol (topical estrogen), and GHK-Cu. A valid prescription from a licensed healthcare provider is required. A telehealth consultation, full medical intake, and thorough patient counseling, including discussion of all active ingredient profiles, contraindications, and the retinoid adjustment period, are required before dispensing.

Side effects reflect the four-active formula. Tretinoin-related adjustment effects (redness, peeling, dryness) during the first 2 to 4 weeks are typically less pronounced than tretinoin-only preparations due to dual tolerability buffering by niacinamide and GHK-Cu. Increased UV sensitivity requires mandatory daily SPF. GHK-Cu may produce a transient blue tint in saliva or at the application site, this is cosmetically benign and resolves rapidly. Estriol may rarely cause mild systemic estrogenic effects (breast tenderness) with significant absorption. Copper sensitivity is a rare but possible reaction. Report any persistent irritation beyond the normal adjustment period, unexpected systemic symptoms, or signs of pregnancy to your provider immediately.

Absolutely contraindicated during pregnancy, tretinoin is teratogenic and must be discontinued if pregnancy occurs or is planned; reliable contraception is required. Not appropriate during breastfeeding. Patients with copper sensitivity or allergy, known retinoid sensitivity, active inflammatory or eczematous facial skin, or a personal history of hormone-sensitive malignancies (estrogen receptor-positive breast or endometrial cancer) must discuss use with their provider or oncologist before initiating. Do not apply to actively inflamed, broken, or sunburned skin.

Other topical retinoids must not be used concurrently, combining retinoid-class products dramatically increases irritation without benefit. Benzoyl peroxide inactivates tretinoin on direct contact. AHAs and BHAs increase barrier disruption risk during the retinoid adjustment period. Copper-chelating topicals or high-dose zinc supplementation may interact with GHK-Cu's copper component. Patients on oral hormonal therapies, including HRT or oral contraceptives, should ensure all providers are aware of the estriol component. Photosensitizing medications require heightened vigilance with mandatory daily SPF.

Patients with a history of hormone-sensitive malignancy must have oncological clearance before using any estriol-containing formula. Those with copper metabolism disorders (Wilson's disease) must not use GHK-Cu. Active inflammatory skin conditions must be stable before initiating. Known retinoid sensitivity is a contraindication. Your provider will conduct a full medical and dermatological review before prescribing and will confirm this is the appropriate formulation for your skin condition and health profile.